Yufeng Wang China

一家源于China的处于临床阶段的生物技术公司,聚焦于研发自身免疫疾病领域的创新药,为China和全世界患者提供未满足的临床用药。

Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
License in/out
Headquartner in China
Biotech/Pharma Asset Stage
Yufeng Wang
Reistone Biopharma
Senior Director BD 

Mei Wang China

biotech focusing on world leading r&d to solve unmet medical needs
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
dizal pharmaceutical
team leader 

Yuqi Wang China

QiRun Biotech is focused on Parkinson's disease CDSS research and development. Currently PDCARE program has achieved cooperation With China pharmaceutical university and hospital's support.
Partnering Objectives
Headquartner in China
QiRun Biotech
Founder 

Ms. Danni Wang China

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Licensing-out and Licensing-in of targeted therapeutic areas
Headquartner in China
Harbour BioMed
Senior Director, Business Development 
Functionality

Dr. Duan Wang China

Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.
Company Size (Fulltime employees)
Please specify your partnering goal
Looking for Assets to in license and global partners
Headquartner in China
Biotech/Pharma Category
Assets Information 1
SHR-1701|SHR-1701is an anti-PD-L1/TGF-βRII bi-functional fusion protein that inhibits PD-L1 andTGF-β. It is currently under phase II and phase I clinical development in China and Australia, respectively. Preliminary data from SHR-1701’s two phase I trials showed promising efficacy and safety.|Solid tumor|
Assets Information 2
Pyrotinib|Pyrotinib is a novel selective tyrosine kinase inhibitor of EGFR/HER2/HER4, with superior efficacy vs. lapatinib. Global registrational trial ongoing; approved in China.|HER2-positive breast cancer|
Assets Information 3
Fluzoparib|Fluzoparib is a PARP inhibitor to address ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and other advanced solid tumors.|Solid tumor|
Biotech/Pharma Asset Stage
Jiangsu Hengrui Pharma
Associate Director of BD 
Functionality

Ms Luyao Wang China

Company Size (Fulltime employees)
Year of foundation
5
Biotech/Pharma Category
Jacobio Pharmaceuticals
Director of PR 
Functionality

Miss Chara Wang China

Big Pharma
Website:
sanofi
Company Size (Fulltime employees)
Please specify your partnering goal
understand the mkt
Headquartner in China
Biotech/Pharma Category
Sanofi
FBP 
Functionality

William Wang China

Pls check us at company website.
Partnering Objectives
Headquartner in China
Tianda Pharmaceutical Ltd
EVP 

Ying Wang China

Pharma and diagnostics
Website:
Roche.com
Headquartner in China
Roche
BD director 

Dr. Weiqing Wang China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
AnHeart Therapeutics
Associate Director of BD 
Functionality